|Bid||32.12 x 900|
|Ask||32.60 x 2200|
|Day's Range||30.71 - 33.61|
|52 Week Range||9.53 - 70.29|
|Beta (5Y Monthly)||1.77|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb. 28, 2022 - Mar. 04, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||72.38|
Shares of ChemoCentryx (NASDAQ: CCXI), a mid-cap biopharmaceutical company, fell by a noteworthy 41.2% over the course of 2021, according to data provided by S&P Global Market Intelligence. ANCA-vasculitis is an autoimmune disorder characterized by swelling and damage to small blood vessels. Although the Food and Drug Administration (FDA) ultimately approved Tavneos on Oct. 8, 2021, the drug's fate was far from certain due to a mixed advisory committee (adcom) meeting earlier in the year.
ChemoCentryx, Inc. ( NASDAQ:CCXI ) is possibly approaching a major achievement in its business, so we would like to...
SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences: 40th Annual J.P. Morgan Healthcare ConferenceWednesday, January 12 at 4:30 p.m. Eastern Time H.C. Wainwright Virtual BioConnect ConferenceOn-demand presentation available beginning Monday, January 10 at 7:00 a.m. Eastern Time A live audio webcast of the J.P. Morgan presenta